New research highlights potential breakthroughs in obsessive-compulsive disorder treatment

Recent research is advancing the understanding and treatment of obsessive-compulsive disorder (OCD). Studies have identified the role of neurotransmitters, such as glutamate and GABA, in OCD, suggesting new drug development opportunities. Researchers have also discovered elevated levels of a protein called immunomodulin in OCD patients, which may lead to targeted therapies. Additionally, a study showed that gut microbiota could influence OCD behaviors, indicating a potential new treatment avenue. New treatments like ketamine and transcranial magnetic stimulation (TMS) are being explored. Ketamine may enhance cognitive behavioral therapy effectiveness, while TMS has shown promise in reducing symptoms for some patients.